Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.67 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.67 |
| ▸ | ACHE | P22303 | 1/20 | 0.63 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP4 | P49662 | 1/20 | 0.44 |
| ▸ | CASP5 | P51878 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12950312 | 0.98 | CHRM5 (0.62) | CHRM5ADRA2CACHEHSD11B1OPRM1 | |
| SCHEMBL27423846 | 0.93 | CHRM5 (0.56) | CHRM5ADRA2CACHEHSD11B1OPRM1 | |
| SCHEMBL3477990 | 0.88 | CHRM5 (0.48) | CHRM5ADRA2CACHEHSD11B1OPRM1 | |
| SCHEMBL5376134 | 0.88 | CHRM5 (0.84) | CHRM5ADRA2CACHEOPRM1OPRL1 | |
| SCHEMBL11596303 | 0.88 | CHRM5 (0.84) | CHRM5ADRA2CACHEOPRM1OPRL1 | |
| SCHEMBL26480974 | 0.86 | ACHE (0.50) | CHRM5ADRA2CACHEHSD11B1OPRM1 | |
| SCHEMBL22520700 | 0.86 | ACHE (0.50) | CHRM5ADRA2CACHEHSD11B1OPRM1 | |
| SCHEMBL21085341 | 0.84 | CHRM5 (0.52) | CHRM5ADRA2CACHEHSD11B1OPRM1 | |
| SCHEMBL24723958 | 0.83 | CHRM5 (0.61) | CHRM5ADRA2CACHEOPRM1OPRL1 | |
| SCHEMBL11919255 | 0.82 | CHRM5 (0.54) | CHRM5ADRA2CACHEHSD11B1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400499-A1 | GLUTARIMIDE COMPOUND AND USE THEREOF | Medshine Discovery Inc. (CN) | 2024-07-17 | — | — | EP | disclosed |
| US-20230339874-A1 | PIPERAZINYL COMPOUNDS AND METHODS FOR TREATING NEMATODE INFECTIONS | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2023-10-26 | — | — | US | disclosed |
| US-20230339874-A1 | PIPERAZINYL COMPOUNDS AND METHODS FOR TREATING NEMATODE INFECTIONS | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2023-10-26 | — | — | US | disclosed |
| US-20200239486-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | G1 THERAPEUTICS, INC. (US) | 2020-07-30 | — | — | US | disclosed |
| US-8119654-B2 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119654-B2 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2012-02-21 | — | — | US | disclosed |
| WO-2011117381-A1 | B-RAF KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-29 | — | — | WO | disclosed |
| US-20100179140-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100179140-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100121049-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100121049-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-7652028-B2 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652028-B2 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-20100004220-A1 | Indenoisoquinolinone Analogs and Methods of Use Thereof | INOTEK PHARMACEUTICALS CORPORATION | 2010-01-07 | — | — | US | disclosed |
| WO-2008106619-A2 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2008-09-04 | — | — | WO | disclosed |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339874-A1 | PIPERAZINYL COMPOUNDS AND METHODS FOR TREATING NEMATODE INFECTIONS | EPX, EGLN3, NISCH | CHRM5 1573/4885ADRA2C 1167/4885ACHE 64/4885 |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | TNNI3, IDH2, GLS | CHRM5 1546/4885ADRA2C 315/4885ACHE 1151/4885 |
| US-20200239486-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | TYMS, TYMP, DPYD | CHRM5 4882/4885ADRA2C 4751/4885ACHE 4874/4885 |
| US-20100121049-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | TNNI3, IDH2, GLS | CHRM5 1546/4885ADRA2C 315/4885ACHE 1151/4885 |
| US-20100004220-A1 | Indenoisoquinolinone Analogs and Methods of Use Thereof | TNNI3, IDH2, GLS | CHRM5 1546/4885ADRA2C 315/4885ACHE 1151/4885 |
| US-20100179140-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | TNNI3, IDH2, GLS | CHRM5 1546/4885ADRA2C 315/4885ACHE 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.